&. Le-zonisamide-montre-une-certaine-efficacité-dans-le-traitement-de-l and . Hb-(mcelroy, Le zonisamide s'est révélé supérieur au placebo en ce qui concerne la réduction de la fréquence des crises de boulimie, du poids corporel, de l'IMC et des mesures de la gravité globale, de la désinhibition alimentaire et des caractéristiques obsessionnelles-compulsives

. Mcelroy, tels que des troubles psychologiques et cognitifs ainsi que des fractures osseuses, 2012.

. Mcelroy, mais apporte une perte de poids significative (moins 1,17 kg contre 0,15 kg pour le placebo) et une réduction plus importante des taux de glucose, d'insuline et de triglycérides à jeun, La lamotrigine n'est pas supérieure au placebo pour réduire les crises hyperphagiques de l'HB, 2012.

, Prise en charge des toxicomanies ou autres dépendances associées Médicaments agissants sur les récepteurs aux opiacés

, La naltrexone s'est montrée favorable pour des doses suprathérapeutiques (200 à 400 mg / jour) en monothérapie et des doses de 100 mg / jour en association avec la fluoxétine, Les traitements « anti-dépendance » cités dans le traitement de la BN ont été aussi testés dans l'HB

. Mcelroy, D'autre part, Les résultats de petits ECR portant sur des antagonistes des opioïdes (ALKS-33 et GSK1521498), publiés récemment, sont plus mitigés, voire même négatifs, 2013.

. Affsaps, Evaluation du potentiel d'abus et de dépendance de la Lisdexamphétamine, 2011.

M. Aigner, J. Treasure, W. Kaye, and S. Kasper, World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Pharmacological Treatment of Eating Disorders, The WFSBP Task Force on Eating Disorders, vol.12, pp.400-443, 2011.

J. Alcock, C. C. Maley, and C. A. Aktipis, Is eating behavior manipulated by the gastrointestinal microbiota ? Evolutionary pressures and potential mechanisms, Prospects & Overviews. BioEssays, vol.36, issue.10, pp.940-949, 2014.

K. C. Alisson and . Rct, Liraglutide 3.0mg/d for the Treatment of Binge Eating Disorder

, American Psychiatric Association. DSM 5 Manuel diagnostique et statistique des troubles mentaux, 2013.

E. J. Anderson, I. Çakir, S. J. Carrington, R. D. Cone, M. Ghamari-langroudi et al., 60 YEARS OF POMC: Regulation of feeding and energy homeostasis by ?-MSH, J Mol Endocrinol, vol.56, issue.4, pp.157-174, 2016.

A. Andries, J. Frystyk, A. Flyvbjerg, and R. K. Støving, Dronabinol in severe, enduring anorexia nervosa: a randomized controlled trial, Int J Eat Disord, vol.47, issue.1, pp.18-23, 2014.

, Acomplia® : suspension de l'autorisation de mise sur le marché -Communiqué, ANSM, 2019.

, Cycloserine, vol.250, 2019.

A. , ANSM octroie une autorisation de mise sur le marché pour une utilisation du baclofène dans l'alcoolo-dépendance, Communique, 2019.

, ANSM, Marinol® 2,5 mg capsule molle, 2019.

, Méthylphénidate : données d'utilisation et de sécurité d, ANSM, 2017.

R. Ansm and . Buspirone-mylan-10mg,

, Treatment of Patients With Eating Disorders, Third Edition. 1 re éd, APA, 2006.

D. Atalayer, C. Gibson, A. Konopacka, and A. Geliebter, Ghrelin and eating disorders, Prog Neuropsychopharmacol Biol Psychiatry, vol.40, pp.70-82, 1982.

A. Avasthi, A. Sharma, and S. Grover, Clinical Practice Guidelines for the Management of Obsessive-Compulsive Disorder in Children and Adolescents, Indian J Psychiatry, vol.61, issue.2, pp.306-316, 2019.

Y. Avraham, I. Paturski, I. Magen, L. Vorobiev, and E. M. Berry, 2-Arachidonoylglycerol as a possible treatment for anorexia nervosa in animal model in mice, Brain Res, vol.1670, pp.185-190, 2017.

A. B. Ayaz, M. Karkucak, M. Ayaz, S. Gokce, E. Kayan et al., Oxytocin system social function impacts in children with attention-deficit/hyperactivity disorder, Am J Med Genet Part B Neuropsychiatr Genet Off Publ Int Soc Psychiatr Genet, vol.168, issue.7, pp.609-616, 2015.

A. K. Ayton, A. Azaz, and D. F. Horrobin, A pilot open case series of Ethyl-EPA supplementation in the treatment of anorexia nervosa, Prostaglandins Leukot Essent Fatty Acids, vol.71, issue.4, pp.205-209, 2004.

S. M. Bahr, B. C. Tyler, N. Wooldridge, B. D. Butcher, T. L. Burns et al., Use of the second-generation antipsychotic, risperidone, and secondary weight gain are associated with an altered gut microbiota in children, Transl Psychiatry, vol.5, p.652, 2015.

J. H. Baker, K. Schaumberg, and M. A. Munn-chernoff, Genetics of Anorexia Nervosa, Curr Psychiatry Rep, vol.19, issue.11, p.84, 2017.

D. S. Baldwin, J. A. Den-boer, G. Lyndon, B. Emir, E. Schweizer et al., Efficacy and safety of pregabalin in generalised anxiety disorder : A critical review of the literature, J Psychopharmacol (Oxf), vol.29, issue.10, pp.1047-1060, 2015.

B. Bandelow, S. Michaelis, and D. Wedekind, Treatment of anxiety disorders, Dialogues Clin Neurosci, vol.19, issue.2, pp.93-107, 2017.

B. Bandelow, L. Sher, R. Bunevicius, E. Hollander, S. Kasper et al., Guidelines for the pharmacological treatment of anxiety disorders, obsessive-compulsive disorder and posttraumatic stress disorder in primary care, Int J Psychiatry Clin Pract, vol.16, issue.2, pp.77-84, 2012.

M. Bauer, A. Pfennig, E. Severus, P. C. Whybrow, J. Angst et al., World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for Biological Treatment of Unipolar Depressive Disorders, Part 1 : Update 2013 on the acute and continuation treatment of unipolar depressive disorders, World J Biol Psychiatry, vol.14, issue.5, pp.334-385, 2013.

R. De-beaurepaire, B. Joussaume, A. Rapp, and P. Jaury, Treatment of Binge Eating Disorder With High-Dose Baclofen: A Case Series, J Clin Psychopharmacol, vol.35, issue.3, pp.357-359, 2015.

N. T. Bello and A. Hajnal, Dopamine and binge eating behaviors, Pharmacol Biochem Behav, vol.97, issue.1, pp.25-33, 2010.

N. T. Bello and B. L. Yeomans, Safety of pharmacotherapy options for bulimia nervosa and binge eating disorder, Expert Opin Drug Saf, vol.17, issue.1, pp.17-23, 2018.

A. Benyaich and K. Benyaich, Les peptides orexigènes et anorexigènes impliqués dans la régulation centrale et périphérique du comportement alimentaire. Pratiques en Nutrition : santé et alimentation, 2017.

L. A. Berner, T. A. Brown, J. M. Lavender, E. Lopez, C. E. Wierenga et al., Neuroendocrinology of reward in anorexia nervosa and bulimia nervosa: Beyond leptin and ghrelin, Mol Cell Endocrinol, 2018.

C. L. Birmingham and S. Gritzner, How does zinc supplementation benefit anorexia nervosa?, Eat Weight Disord, vol.11, issue.4, pp.109-111, 2006.

C. Blanchet, S. Guillaume, F. Bat-pitault, M. Carles, J. Clarke et al., Medication in AN : A Multidisciplinary Overview of Meta-Analyses and Systematic Reviews, J Clin Med, vol.8, issue.2, p.278, 2019.

A. Blasio, L. Steardo, V. Sabino, and P. Cottone, Opioid system in the medial prefrontal cortex mediates binge-like eating, Addict Biol, vol.19, issue.4, pp.652-662, 2014.

M. H. Bloch and E. A. Storch, Assessment and Management of Treatment-Refractory Obsessive-Compulsive Disorder in Children, J Am Acad Child Adolesc Psychiatry, vol.54, issue.4, pp.251-262, 2015.

P. Bosanac, S. Kurlender, T. Norman, K. Hallam, K. Wesnes et al., An openlabel study of quetiapine in anorexia nervosa, Hum Psychopharmacol, vol.22, issue.4, pp.223-230, 2007.

P. Bozzatello, E. Brignolo, E. D. Grandi, and S. Bellino, Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data, J Clin Med, vol.5, issue.8, p.67, 2016.

J. Breton, P. Déchelotte, and D. Ribet, Intestinal microbiota and Anorexia Nervosa, Clin Nutr Exp, 2019.

J. Breton, R. Legrand, K. Akkermann, A. Järv, J. Harro et al., Elevated plasma concentrations of bacterial ClpB protein in patients with eating disorders, Int J Eat Disord, vol.49, issue.8, pp.805-808, 2016.

T. Brockmeyer, H. Friederich, and U. Schmidt, Advances in the treatment of anorexia nervosa : a review of established and emerging interventions, Psychol Med, vol.48, issue.8, pp.1228-1256, 2018.

A. I. Broft, A. Spanos, R. L. Corwin, L. Mayer, J. Steinglass et al., Baclofen for binge eating : An open-label trial, Int J Eat Disord, vol.40, issue.8, pp.687-691, 2007.

K. A. Brownley, V. Holle, A. Hamer, R. M. , L. Via et al., A double-blind, randomized pilot trial of chromium picolinate for binge eating disorder : results of the Binge Eating and Chromium (BEACh) study, J Psychosom Res, vol.75, issue.1, pp.36-42, 2013.

C. Calandra, R. G. Russo, and M. Luca, Bupropion Versus Sertraline in the Treatment of Depressive Patients with Binge Eating Disorder: Retrospective Cohort Study, Psychiatr Q, vol.83, issue.2, pp.177-185, 2012.

A. Capasso, C. Putrella, and W. Milano, Recent clinical aspects of eating disorders, Rev Recent Clin Trials, vol.4, issue.1, pp.63-69, 2009.

S. Caspar-bauguil, E. Montastier, F. Galinon, D. Frisch-benarous, R. Salvayre et al., Anorexia nervosa patients display a deficit in membrane long chain poly-unsaturated fatty acids, Clin Nutr, vol.31, issue.3, pp.386-390, 2012.

G. B. Cassano, M. Miniati, S. Pini, A. Rotondo, S. Banti et al., Six-month open trial of haloperidol as an adjunctive treatment for anorexia nervosa: a preliminary report, Int J Eat Disord, vol.33, issue.2, pp.172-177, 2003.

T. Charpeaud, J. Genty, S. Destouches, A. Yrondi, S. Lancrenon et al., Prise en charge des troubles dépressifs résistants : recommandations françaises formalisées par des experts de l'AFPBN et de la fondation FondaMental, L'Encephale, vol.43, issue.4, pp.1-24, 2017.

J. Clarke, N. Ramoz, A. Fladung, and P. Gorwood, Higher reward value of starvation imagery in anorexia nervosa and association with the Val66Met BDNF polymorphism, Transl Psychiatry, vol.6, issue.6, p.829, 2016.

A. Claudino, I. De-oliveira, J. Appolinario, T. Cordás, M. Duchesne et al., Doubleblind, randomized, placebo-controlled trial of topiramate plus cognitive-behavior therapy in binge-eating disorder, J Clin Psychiatry, vol.68, issue.9, pp.1324-1332, 2007.

. Clinicaltrials and . Gov, Fecal Microbiota Transplantation (FMT) in Treatment of Severe and Enduring Anorexia Nervosa

J. Cohen, A. Dervaux, and X. Laqueille, Le topiramate a-t-il un intérêt en addictologie ? Presse Médicale, vol.43, pp.892-901, 2014.

J. Cottraux, Trouble obsessionnel compulsif, EMC -Psychiatrie, vol.14, issue.1, pp.1-15, 2016.

J. F. Cryan and T. G. Dinan, Mind-altering microorganisms: the impact of the gut microbiota on brain and behaviour, Nat Rev Neurosci, vol.13, issue.10, pp.701-712, 2012.

K. M. Culbert, S. E. Racine, and K. L. Klump, Hormonal Factors and Disturbances in Eating Disorders, Curr Psychiatry Rep, vol.18, issue.7, p.65

D. J. David and A. M. Gardier, Les bases de pharmacologie fondamentale du système sérotoninergique : application à la réponse antidépressive. L'Encéphale, vol.42, pp.255-263, 2016.

C. A. Davis, R. D. Levitan, C. Reid, J. C. Carter, A. S. Kaplan et al., Dopamine for « wanting » and opioids for « liking »: a comparison of obese adults with and without binge eating, Obes Silver Spring Md, vol.17, issue.6, pp.1220-1225, 2009.

D. Vadder, F. Mithieux, and G. , Contrôle de la glycémie par l'axe nerveux intestin-cerveau, Med Sci, issue.2, pp.168-173, 2015.

N. C. De-clercq, M. N. Frissen, M. Davids, A. K. Groen, and M. Nieuwdorp, Weight Gain after Fecal Microbiota Transplantation in a Patient with Recurrent Underweight following Clinical Recovery from Anorexia Nervosa, Psychother Psychosom, vol.88, issue.1, pp.58-60, 2019.

A. Delini-stula, G. Bondolfi, and E. Holsboer-trachsler, Actual therapeutic options in the treatment of generalized anxiety disorders, Rev Med Suisse, vol.6, issue.255, pp.1370-1374, 2010.

A. Depping, K. Komossa, W. Kissling, and S. Leucht, Second-generation antipsychotics for anxiety disorders, Cochrane Database of Systematic Reviews, p.12, 2010.

E. Disse, La ghréline : physiologie et perspectives thérapeutiques, vol.53, pp.357-363, 2011.

M. Dold, M. Aigner, M. Klabunde, J. Treasure, and S. Kasper, Second-Generation Antipsychotic Drugs in Anorexia Nervosa : A Meta-Analysis of Randomized Controlled Trials, Psychother Psychosom, vol.84, issue.2, pp.110-116, 2015.

M. Dold, L. Bartova, J. Mendlewicz, D. Souery, A. Serretti et al., Clinical correlates of augmentation/combination treatment strategies in major depressive disorder, Acta Psychiatr Scand, vol.137, issue.5, pp.401-412, 2018.

N. Dong, V. Nezgovorova, K. Hong, and E. Hollander, Pharmacotherapy in body dysmorphic disorder : relapse prevention and novel treatments, Expert Opin Pharmacother, pp.1-9, 2019.

O. Doumy, D. Bennabi, W. El-hage, N. Allaïli, R. Bation et al., Dépression résistante : les stratégies de potentialisation, Presse Médicale, vol.45, issue.3, pp.338-349, 2016.

P. Duriez, A. Guy-rubin, and P. Gordwood, L'anorexie mentale : peur de prendre ou plaisir de perdre ?, Nutr Endocrinol, vol.82, issue.15, pp.51-53, 2017.

K. T. Eddy, E. A. Lawson, C. Meade, E. Meenaghan, S. E. Horton et al., Appetite Regulatory Hormones in Women With Anorexia Nervosa: Binge-Eating/Purging Versus Restricting Type, J Clin Psychiatry, vol.76, issue.1, pp.19-24, 2014.

W. El-hage and E. Fakra, Réponse non suffisante : quelle prise en charge ? L'Encéphale, vol.42, pp.39-47, 2014.

E. Adlumiz, Cycloserine -Summary of Product Characteristics (SmPC)

M. Etchegaray and P. Hardy, Traitement des troubles anxieux généralisés, Presse Médicale, vol.37, issue.5, pp.859-866, 2008.

E. Fakra, R. Belzeaux, J. M. Azorin, and M. Adida, Troubles affectifs et troubles des conduites alimentaires. L'Encéphale, vol.40, pp.46-50, 2014.

P. L. Faris, S. W. Kim, W. H. Meller, R. L. Goodale, S. A. Oakman et al., Effect of decreasing afferent vagal activity with ondansetron on symptoms of bulimia nervosa: a randomised, double-blind trial, The Lancet, vol.355, issue.9206, pp.792-797, 2000.

S. Faure and N. Etienne-selloum, Du mécanisme d'action des médicaments à la thérapeutique, 2015.

L. Ferrier-avenet, Troubles du comportement alimentaire de l'adulte: réalisation d'une vidéo de psychoéducation, 2015.

S. O. Fetissov, Role of the gut microbiota in host appetite control: bacterial growth to animal feeding behaviour, Nat Rev Endocrinol, vol.13, issue.1, pp.11-25, 2017.
URL : https://hal.archives-ouvertes.fr/hal-02303770

S. O. Fetissov, H. Sinno, M. Coquerel, Q. , D. Rego et al., Emerging role of autoantibodies against appetite-regulating neuropeptides in eating disorders, Nutrition, vol.24, issue.9, pp.854-859, 2008.

M. M. Fichter, R. Krüger, W. Rief, R. Holland, and J. Döhne, Fluvoxamine in prevention of relapse in bulimia nervosa : effects on eating-specific psychopathology, J Clin Psychopharmacol, vol.16, issue.1, pp.9-18, 1996.

K. K. Fitzpatrick and J. Lock, Anorexia nervosa, BMJ Clin Evid, vol.4, p.1011, 2011.

M. F. Flament, H. Bissada, and W. Spettigue, Evidence-based pharmacotherapy of eating disorders, Int J Neuropsychopharmacol, vol.15, issue.02, pp.189-207, 2012.

G. K. Frank, Could Dopamine Agonists Aid in Drug Development for Anorexia Nervosa? Front Nutr, vol.19, pp.1-9, 2014.

G. K. Frank, Aripiprazole, a partial dopamine agonist to improve adolescent anorexia nervosa-A case series, Int J Eat Disord, vol.49, issue.5, pp.529-533, 2016.

G. K. Frank, M. E. Shott, J. O. Hagman, M. A. Schiel, M. C. Deguzman et al., The partial dopamine D2 receptor agonist aripiprazole is associated with weight gain in adolescent anorexia nervosa, Int J Eat Disord, vol.50, issue.4, pp.447-450, 2017.

A. De-franssu and M. Rodde, Mise en garde sur le détournement de l'usage d'Epitomax® à visée amaigrissante

, ANSM, 2011.

M. Galmiche, P. Déchelotte, G. Lambert, and M. Tavolacci, Prevalence of eating disorders over the 2000-2018 period : a systematic literature review, Am J Clin Nutr, vol.109, issue.5, pp.1402-1413, 2019.

D. M. Garner, M. L. Anderson, C. D. Keiper, R. Whynott, and L. Parker, Psychotropic medications in adult and adolescent eating disorders : clinical practice versus evidence-based recommendations, Eat Weight Disord, vol.21, issue.3, pp.395-402, 2016.

B. Gatta-cherifi, Neurobiologie de la prise alimentaire, Médecine des Maladies Métaboliques, vol.6, pp.115-119, 2012.

C. Gauthier, L. Souaiby, M. Poirier, J. Olié, and M. Krebs, Antidépresseurs : aspects pharmacologiques, EMC -Psychiatrie, vol.14, issue.2, pp.1-11, 2016.

N. Germain, B. Galusca, D. Grouselle, D. Frere, S. Billard et al., Ghrelin and Obestatin Circadian Levels Differentiate Bingeing-Purging from Restrictive Anorexia Nervosa, J Clin Endocrinol Metab, vol.95, issue.6, pp.3057-3062, 2010.

K. Giel, S. Zipfel, and M. Hallschmid, Oxytocin and Eating Disorders : A Narrative Review on Emerging Findings and Perspectives, Curr Neuropharmacol, vol.16, issue.8, pp.1111-1121, 2018.

N. Golden and E. Attia, Psychopharmacology of eating disorders in children and adolescents, Pediatr Clin North Am, vol.58, issue.1, pp.121-138, 2011.

P. Goulia, C. Mantas, I. D. Bassukas, and T. Hyphantis, Treatment with risperidone and venlafaxine of a patient with double-coded diagnosis of body dysmorphic disorder and delusional disorder somatic type, Hippokratia, vol.15, issue.3, pp.286-287, 2011.

S. G. Gowers, A. F. Clark, C. Roberts, S. Byford, B. Barrett et al., A randomised controlled multicentre trial of treatments for adolescent anorexia nervosa including assessment of cost-effectiveness and patient acceptability -the TOuCAN trial, Health Technol Assess, vol.14, issue.15, pp.1-98, 2010.

J. E. Grant, Successful treatment of nondelusional body dysmorphic disorder with olanzapine: a case report, J Clin Psychiatry, vol.62, issue.4, pp.297-298, 2001.

K. P. Grootens, A. Meijer, E. G. Hartong, B. Doornbos, P. R. Bakker et al., Weight changes associated with antiepileptic mood stabilizers in the treatment of bipolar disorder, Eur J Clin Pharmacol, vol.74, issue.11, pp.1485-1489, 2018.

A. I. Guerdjikova, T. J. Blom, B. E. Martens, P. E. Keck, and S. L. Mcelroy, Zonisamide in the treatment of bulimia nervosa : An open-label, pilot, prospective study, Int J Eat Disord, vol.46, issue.7, pp.747-750, 2013.

D. J. Haleem, Improving therapeutics in anorexia nervosa with tryptophan, Life Sci, vol.178, pp.87-93, 2017.

V. Hausswolff-juhlin, Y. Brooks, S. J. Larsson, and M. , The neurobiology of eating disorders-a clinical perspective, Acta Psychiatr Scand, vol.131, issue.4, pp.244-255, 2015.

J. Helfer, A. Favaro, and A. Ambresin, Somatic care and complications of anorexia nervosa in adolescent girls, Rev Med Suisse, vol.12, issue.522, pp.1129-1132, 2016.

B. Herpertz-dahlmann, J. Seitz, and J. Baines, Food matters : how the microbiome and gut-brain interaction might impact the development and course of anorexia nervosa, Eur Child Adolesc Psychiatry, vol.26, issue.9, pp.1031-1041, 2017.

L. L. Van-den-heuvel and G. P. Jordaan, The psychopharmacological management of eating disorders in children and adolescents, J Child Adolesc Ment Health, vol.26, issue.2, pp.125-137, 2014.

H. Himmerich, J. Bentley, C. Kan, and J. Treasure, Genetic risk factors for eating disorders : an update and insights into pathophysiology, Ther Adv Psychopharmacol, vol.9, pp.1-20, 2019.

H. Himmerich, M. Hotopf, H. Shetty, U. Schmidt, J. Treasure et al., Psychiatric comorbidity as a risk factor for the mortality of people with bulimia nervosa, Soc Psychiatry Psychiatr Epidemiol, pp.1-9, 2019.

H. Himmerich, Psychopharmacological advances in eating disorders, Expert Rev Clin Pharmacol, vol.11, issue.1, pp.95-108, 2018.

M. Hotta, R. Ohwada, T. Akamizu, T. Shibasaki, and K. Kangawa, Therapeutic Potential of Ghrelin in Restricting-Type Anorexia Nervosa, Methods Enzymol, vol.514, pp.381-398, 2012.

J. I. Hudson, Antiglutamatergic Treatment of Bulimia Nervosa and Body Dysmorphic Disorder : An Open-Label Trial of Memantine, Clinicaltrials.gov, 2009.

J. I. Hudson, S. L. Mcelroy, M. C. Ferreira-cornwell, J. Radewonuk, and M. Gasior, Efficacy of Lisdexamfetamine in Adults With Moderate to Severe Binge-Eating Disorder : A Randomized Clinical Trial, JAMA Psychiatry, vol.74, issue.9, p.903, 2017.

P. H. Hutson, I. M. Balodis, and M. N. Potenza, Binge-eating disorder : Clinical and therapeutic advances, Pharmacol Ther, vol.182, pp.15-27, 2018.

, ISAPP, International Scientific Association for Probiotics and Prebiotics

E. Isolauri, P. M. Sherman, and W. A. Walker, Intestinal Microbiome : Functional Aspects in Health and Disease, Nestlé Nutr Inst Workshop Ser, vol.88, pp.45-53, 2017.

H. Javelot, Psychopharmacologie de l'anxiété et de la dépression : aspects historiques, traitements actuels et perspectives, Ann Pharm Fr, vol.74, issue.2, pp.93-118, 2016.

M. Jourdain, L'évaluation des intérêts des antipsychotiques dans l'anorexie mentale : de la neurobiologie aux essais cliniques, Th D Pharm, 2011.

N. J. Kalk and A. R. Lingford-hughes, The clinical pharmacology of acamprosate, Br J Clin Pharmacol, vol.77, issue.2, pp.315-323, 2014.

P. A. Kantak, D. N. Bobrow, and J. G. Nyby, Obsessive-compulsive-like behaviors in house mice are attenuated by a probiotic (Lactobacillus rhamnosus GG), Behav Pharmacol, vol.25, issue.1, pp.71-79, 2014.

W. H. Kaye, T. Nagata, T. E. Weltzin, L. K. Hsu, M. S. Sokol et al., Double-blind placebo-controlled administration of fluoxetine in restricting-and restricting-purging-type anorexia nervosa, Biol Psychiatry, vol.49, issue.7, pp.644-652, 2001.

M. N. Khatib, A. Gaidhane, S. Gaidhane, and Z. S. Quazi, Ghrelin as a Promising Therapeutic Option for Cancer Cachexia, Cell Physiol Biochem, vol.48, issue.5, pp.2172-2188, 2018.

A. Khlaifia, I. Matias, D. Cota, and F. Tell, Nutritional status-dependent endocannabinoid signalling regulates the integration of rat visceral information, J Physiol, vol.595, issue.11, pp.3267-3285, 2017.

H. Kober and R. G. Boswell, Potential psychological & neural mechanisms in binge eating disorder: Implications for treatment, Clin Psychol Rev, vol.60, pp.32-44, 2018.

I. Kollei, S. Horndasch, Y. Erim, and A. Martin, Visual selective attention in body dysmorphic disorder, bulimia nervosa and healthy controls, J Psychosom Res, vol.92, pp.26-33, 2017.

L. A. Kotler, M. J. Devlin, M. Davies, and B. T. Walsh, An open trial of fluoxetine for adolescents with bulimia nervosa, J Child Adolesc Psychopharmacol, vol.13, issue.3, pp.329-335, 2003.

M. Kountza, G. Garyfallos, D. Ploumpidis, E. Varsou, and I. Gkiouzepas, La comorbidité psychiatrique de l'anorexie mentale : une étude comparative chez une population de patients anorexiques français et grecs. L'Encéphale, vol.44, pp.429-434, 2017.

G. Krebs and I. Heyman, Obsessive-compulsive disorder in children and adolescents, Arch Dis Child, vol.100, issue.5, pp.495-499, 2015.

M. Lauzon, Quelles sont les meilleures associations d'antidépresseurs dans le cas d'une dépression réfractaire ?, 2019.

R. F. Lawson, Implication de la sérotonine et des récepteurs 5-HT2 dans le remodelage valvulaire cardiaque. Th sciences, pharmacologie, 2014.

N. Leblé, L. Radon, M. Rabot, and N. Godart, Manifestations dépressives au cours de l'anorexie mentale : données de la littérature et implications pour une utilisation adaptée des antidépresseurs, L'Encéphale, vol.43, issue.1, pp.62-68, 2017.

J. Lebow, J. A. Chuy, K. Cedermark, K. Cook, and L. A. Sim, The Development or Exacerbation of Eating Disorder Symptoms After Topiramate Initiation, Pediatrics, vol.135, issue.5, pp.1312-1316, 2015.

P. Leombruni, A. Pierò, L. Lavagnino, A. Brustolin, S. Campisi et al., A randomized, double-blind trial comparing sertraline and fluoxetine 6-month treatment in obese patients with Binge Eating Disorder, Prog Neuropsychopharmacol Biol Psychiatry, vol.32, issue.6, pp.1599-1605, 2008.

C. A. Levinson, T. L. Rodebaugh, L. Fewell, A. E. Kass, E. N. Riley et al., D-Cycloserine facilitation of exposure therapy improves weight regain in patients with anorexia nervosa: a pilot randomized controlled trial, J Clin Psychiatry, vol.76, issue.6, pp.787-793, 2015.

L. Lew, Y. Hor, N. A. Yusoff, S. Choi, M. S. Yusoff et al., Probiotic Lactobacillus plantarum P8 alleviated stress and anxiety while enhancing memory and cognition in stressed adults: A randomised, double-blind, placebo-controlled study, Clin Nutr Edinb Scotl, pp.1-14, 2018.

N. Lucas, S. Azhar, C. Deroissart, L. Solliec, M. Dominique et al., Un nouveau probiotique, Hafnia alvei, réduit le gain de poids dans deux modèles murins d'obésité en agissant sur les voies centrales et périphériques de l'homéostasie énergétique, Nutr Clin Métabolisme, vol.33, issue.1, pp.22-23, 2019.

N. Lucas, R. Legrand, C. Bôle-feysot, J. Breton, M. Coëffier et al., , 2019.

, Immunoglobulin G modulation of the melanocortin 4 receptor signaling in obesity and eating disorders, Transl Psychiatry, vol.9, issue.1, p.87

V. Makoundou and A. Golay, Traitements médicamenteux de l'appétit, Rev Médicale Suisse, vol.7, pp.57-60, 2011.

S. Marucci, L. D. Ragione, G. De-iaco, T. Mococci, M. Vicini et al., Anorexia Nervosa and Comorbid Psychopathology, Endocr Metab Immune Disord Drug Targets, vol.18, issue.4, pp.316-324, 2018.

M. Marvanova and K. Gramith, Role of antidepressants in the treatment of adults with anorexia nervosa, Ment Health Clin, vol.8, issue.3, pp.127-137, 2018.

E. Marzola, N. Desedime, C. Giovannone, F. Amianto, S. Fassino et al., Atypical Antipsychotics as Augmentation Therapy in Anorexia Nervosa, PLoS One, vol.10, issue.4, p.125569, 2015.

B. L. Mason, Feeding Systems and the Gut Microbiome: Gut-Brain Interactions With Relevance to Psychiatric Conditions, Psychosomatics, vol.58, issue.6, pp.574-580, 2017.

M. Mauri, M. Miniati, M. G. Mariani, A. Ciberti, and L. Dell'osso, Haloperidol for severe anorexia nervosa restricting type with delusional body image disturbance : a nine-case chart review, Eat Weight Disord, vol.18, issue.3, pp.329-332, 2013.

A. J. Mayhew, M. Pigeyre, J. Couturier, and D. Meyre, An Evolutionary Genetic Perspective of Eating Disorders, Neuroendocrinology, vol.106, issue.3, pp.292-306, 2018.

S. L. Mcelroy, R. Kotwal, A. I. Guerdjikova, J. A. Welge, E. B. Nelson et al., Zonisamide in the Treatment of Binge Eating Disorder With Obesity: A Randomized Controlled Trial, J Clin Psychiatry, vol.68, issue.1, p.172, 2007.

S. L. Mcelroy, Pharmacologic Treatments for Binge-Eating Disorder, J Clin Psychiatry, vol.78, pp.14-19, 2017.

S. L. Mcelroy, A. I. Guerdjikova, R. Kotwal, J. A. Welge, E. B. Nelson et al., , 2007.

, Atomoxetine in the treatment of binge-eating disorder: a randomized placebo-controlled trial, J Clin Psychiatry, vol.68, issue.3, pp.390-398

S. L. Mcelroy, A. I. Guerdjikova, T. J. Blom, S. J. Crow, A. Memisoglu et al., A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder, Int J Eat Disord, vol.46, issue.3, pp.239-245, 2013.

S. L. Mcelroy, A. I. Guerdjikova, B. Martens, P. E. Keck, H. G. Pope et al., Role of Antiepileptic Drugs in the Management of Eating Disorders, CNS Drugs, vol.23, issue.2, pp.139-156, 2009.

S. L. Mcelroy, A. I. Guerdjikova, N. Mori, T. J. Blom, S. Williams et al., , 2015.

, Armodafinil in binge eating disorder: a randomized, placebo-controlled trial, Int Clin Psychopharmacol, vol.30, issue.4, pp.209-215

S. L. Mcelroy, A. I. Guerdjikova, N. Mori, and A. M. O'melia, Current pharmacotherapy options for bulimia nervosa and binge eating disorder, Expert Opin Pharmacother, vol.13, issue.14, pp.2015-2026, 2012.

S. L. Mcelroy, A. I. Guerdjikova, N. Mori, and F. Romo-nava, Progress in Developing Pharmacologic Agents to Treat Bulimia Nervosa, CNS Drugs, vol.33, issue.1, pp.31-46, 2019.

S. L. Mcelroy, A. I. Guerdjikova, E. L. Winstanley, A. M. O'melia, N. Mori et al., , 2011.

, Acamprosate in the treatment of binge eating disorder: A placebo-controlled trial, Int J Eat Disord, vol.44, issue.1, pp.81-90

S. L. Mcelroy, R. Kotwal, P. E. Keck, and H. S. Akiskal, Comorbidity of bipolar and eating disorders: distinct or related disorders with shared dysregulations?, J Affect Disord, vol.86, issue.2-3, pp.107-127, 2005.

C. Mehler-wex, M. Romanos, J. Kirchheiner, and U. M. Schulze, Atypical antipsychotics in severe anorexia nervosa in children and adolescents--review and case reports, Eur Eat Disord Rev J Eat Disord Assoc, vol.16, issue.2, pp.100-108, 2008.

E. Messamore, D. M. Almeida, R. J. Jandacek, and R. K. Mcnamara, Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application, Prog Lipid Res, vol.66, pp.1-13, 2017.

J. Micó and R. Prieto, Elucidating the mechanism of action of pregabalin: ?(2)? as a therapeutic target in anxiety, CNS Drugs, vol.26, issue.8, pp.637-648, 2012.

W. Milano, C. Petrella, C. Sabatino, and A. Capasso, Treatment of bulimia nervosa with sertraline : a randomized controlled trial, Adv Ther, vol.21, issue.4, pp.232-237, 2004.

W. Milano, C. Siano, C. Putrella, and A. Capasso, Treatment of bulimia nervosa with fluvoxamine: a randomized controlled trial, Adv Ther, vol.22, issue.3, pp.278-283, 2005.

M. Miniati, M. Mauri, A. Ciberti, M. G. Mariani, D. Marazziti et al., Psychopharmacological options for adult patients with anorexia nervosa, CNS Spect, vol.21, issue.02, pp.134-142, 2016.

C. M. Mitchell, B. M. Davy, T. M. Halliday, M. W. Hulver, A. P. Neilson et al., The effect of prebiotic supplementation with inulin on cardiometabolic health: Rationale, design, and methods of a controlled feeding efficacy trial in adults at risk of type 2 diabetes, Contemp Clin Trials, vol.45, pp.328-337, 2015.

J. E. Mitchell, J. Roerig, and K. Steffen, Biological therapies for eating disorders, Int J Eat Disord, vol.46, issue.5, pp.470-477, 2013.

H. Möller, I. Bitter, J. Bobes, K. Fountoulakis, C. Höschl et al., Position statement of the European Psychiatric Association (EPA) on the value of antidepressants in the treatment of unipolar depression, Eur Psychiatry J Assoc Eur Psychiatr, vol.27, issue.2, pp.114-128, 2012.

F. Montastruc and L. Saliba, Pharmacovigilance et Pharmacoépidémiologie : Anorexigènes, la série continue !, vol.31, pp.44-54, 2012.

M. Mula, S. Pini, and G. B. Cassano, The Role of Anticonvulsant Drugs in Anxiety Disorders: A Critical Review of the Evidence, J Clin Psychopharmacol, vol.27, issue.3, pp.263-272, 2007.

. Naèssen, Effects of an antiandrogenic oral contraceptive on eating behaviour in women with bulimia -A randomized double blinded, placebo controlled study, Clinical Trials Register, 2019.

S. Naessén, K. Carlström, B. Byström, Y. Pierre, L. Hirschberg et al., Effects of an antiandrogenic oral contraceptive on appetite and eating behavior in bulimic women, Psychoneuroendocrinology, vol.32, issue.5, pp.548-554, 2007.

S. Nakaaki, Y. Murata, and T. A. Furukawa, Efficacy of olanzapine augmentation of paroxetine therapy in patients with severe body dysmorphic disorder, Psychiatry Clin Neurosci, vol.62, issue.3, p.370, 2008.

, Depression in adults: recognition and management, 2019.

N. Niederhoffer, N. Etienne-selloum, and S. Faure, Les différentes familles d'antidépresseurs, Actual Pharm, vol.55, issue.561, pp.1-10, 2016.

M. Novelle and C. Diéguez, Food Addiction and Binge Eating: Lessons Learned from Animal Models, Nutrients, vol.10, issue.1, p.71, 2018.

B. O. Olatunji, C. D. Tart, S. Shewmaker, D. Wall, and J. A. Smits, Mediation of symptom changes during inpatient treatment for eating disorders : the role of obsessive-compulsive features, J Psychiatr Res, vol.44, issue.14, pp.910-916, 2010.

, CIM-10 / ICD-10 Classification internationale des troubles mentaux et des troubles du comportement : Descriptions cliniques et directives pour le diagnostic (F50)

R. M. Pacilio, R. K. Livingston, and M. R. Gordon, The Use of Electroconvulsive Therapy in Eating Disorders : A Systematic Literature Review and Case Report, J ECT, 2019.

D. Paitraud and . Vidal, Mysimba® (naltrexone, bupropion) : une sécurité jugée insuffisante pour être mis sur le marché

P. Paoletti, C. Bellone, and Q. Zhou, NMDA receptor subunit diversity : impact on receptor properties, synaptic plasticity and disease, Nat Rev Neurosci, vol.14, issue.6, pp.383-400, 2013.

S. Pelsy, électroconvulsivothérapie: histoire, pratique actuelle et apport dans la maladie de Parkinson, 2005.

M. Perelló and J. M. Zigman, The Role of Ghrelin in Reward-Based Eating, Biol Psychiatry, vol.72, issue.5, pp.347-353, 2012.

M. Á. Pérez, V. Peñaloza-sancho, J. Ahumada, M. Fuenzalida, and A. Dagnino-subiabre, n -3 Polyunsaturated fatty acid supplementation restored impaired memory and GABAergic synaptic efficacy in the hippocampus of stressed rats, Nutr Neurosci, vol.21, issue.8, pp.556-569, 2018.

M. Perraudin, S. Coulon, G. Willoquet, and B. Welniarz, La prescription hors autorisation de mise sur le marché (hors AMM) en pédopsychiatrie, Inf Psychiatr, vol.94, issue.2, pp.101-107, 2018.

S. J. Persaud and G. A. Bewick, Peptide YY: more than just an appetite regulator, Diabetologia, vol.57, issue.9, pp.1762-1769, 2014.

K. A. Phillips, Olanzapine augmentation of fluoxetine in body dysmorphic disorder, Am J Psychiatry, vol.162, issue.5, pp.1022-1023, 2005.

W. Pitchot, G. Scantamburlo, and M. Ansseau, Les antidépresseurs tricycliques et les IMAO ont-ils encore une place dans le traitement de la dépression, Rev Med Liège, vol.66, issue.3, pp.144-152, 2011.

C. Pittenger and M. H. Bloch, Pharmacological Treatment of Obsessive-Compulsive Disorder, Psychiatr Clin North Am, vol.37, issue.3, pp.375-391, 2014.

F. Plessow, K. T. Eddy, and E. A. Lawson, The Neuropeptide Hormone Oxytocin in Eating Disorders, Curr Psychiatry Rep, vol.20, p.91, 2018.

P. S. Powers, Y. Bannon, R. Eubanks, and T. Mccormick, Quetiapine in anorexia nervosa patients : an open label outpatient pilot study, Int J Eat Disord, vol.40, issue.1, pp.21-26, 2007.

A. C. Prince, S. J. Brooks, D. Stahl, and J. Treasure, Systematic review and meta-analysis of the baseline concentrations and physiologic responses of gut hormones to food in eating disorders, Am J Clin Nutr, vol.89, issue.3, pp.755-765, 2009.

F. Rachid, Repetitive transcranial magnetic stimulation in the treatment of eating disorders : A review of safety and efficacy, Psychiatry Res, vol.269, pp.145-156, 2018.

F. Rachidi and E. Moyse, La neurobiologie de la nutrition I. une grande fonction neuroendocrine, Biomatec Echo, vol.4, issue.7, pp.25-38, 2011.

N. Ramoz, J. Clarke, and P. Gorwood, Génétique et épigénétique des troubles des conduites alimentaires, Biol Aujourdhui, vol.211, issue.1, pp.97-102, 2017.

A. Revet, A. Yrondi, and F. Montastruc, Règles de bon usage des benzodiazépines, Presse Médicale, vol.48, issue.2, pp.215-216, 2018.

D. Rigaud, Rôle des hormones digestives et adipocytaires dans les troubles du comportement alimentaire. Correspo MHDN, vol.18, pp.16-29, 2014.

S. J. Romano, K. A. Halmi, N. P. Sarkar, S. C. Koke, and J. S. Lee, A placebo-controlled study of fluoxetine in continued treatment of bulimia nervosa after successful acute fluoxetine treatment, Am J Psychiatry, vol.159, issue.1, pp.96-102, 2002.

G. Rossi, U. Balottin, M. Rossi, M. Chiappedi, E. Fazzi et al., Pharmacological treatment of anorexia nervosa : a retrospective study in preadolescents and adolescents, Clin Pediatr (Phila), vol.46, issue.9, pp.806-811, 2007.

H. Roux, E. Chapelon, and N. Godart, Épidémiologie de l'anorexie mentale : revue de la littérature, vol.39, pp.85-93, 2013.

J. Russell, S. Maguire, G. E. Hunt, A. Kesby, A. Suraev et al., Intranasal oxytocin in the treatment of anorexia nervosa : Randomized controlled trial during re-feeding, Psychoneuroendocrinology, vol.87, pp.83-92, 2018.

D. L. Safer, FDA approved Medication to Reduce Binge Eating and/or Purging, 2019.

C. Sagheddu, A. L. Muntoni, M. Pistis, and M. Melis, Endocannabinoid Signaling in Motivation, Reward, and Addiction, Int Rev Neurobiol, vol.125, pp.257-302, 2015.

M. Sala, L. Breithaupt, C. M. Bulik, R. M. Hamer, L. Via et al., A Double-Blind, Randomized Pilot Trial of Chromium Picolinate for Overweight Individuals with Binge-Eating Disorder: Effects on Glucose Regulation, J Diet Suppl, vol.14, issue.2, pp.191-199, 2017.

K. V. Sandhu, E. Sherwin, H. Schellekens, C. Stanton, T. G. Dinan et al., Feeding the microbiota-gut-brain axis: diet, microbiome, and neuropsychiatry, Transl Res J Lab Clin Med, vol.179, pp.223-244, 2017.

G. Scantamburlo, M. Hansenne, V. Geenen, J. J. Legros, and M. Ansseau, Additional intranasal oxytocin to escitalopram improves depressive symptoms in resistant depression : an open trial, Eur Psychiatry J Assoc Eur Psychiatr, vol.30, issue.1, pp.65-68, 2015.

J. Schlienger, Nutrition clinique pratique. 3 ème éd, 2018.

F. M. Schmidt, K. C. Kirkby, and H. Himmerich, The TNF-alpha inhibitor Etanercept as monotherapy in treatment -Resistant depression -Report of two cases, Psychiatr Danub, vol.26, issue.3, pp.288-290, 2014.

B. Schoentgen, C. Lancelot, L. Gall, and D. , Comportement alimentaire de l'enfant et de l'adolescent souffrant d'obésité : intérêt d'un couplage des approches neurobiologique et neuropsychologique, Arch Pédiatrie, vol.24, issue.3, pp.273-279, 2017.

J. Seitz, S. Trinh, and B. Herpertz-dahlmann, The Microbiome and Eating Disorders, Psychiatr Clin North Am, vol.42, issue.1, pp.93-103, 2019.

M. Sild and L. Booij, Histone deacetylase 4 (HDAC4) : a new player in anorexia nervosa ?, Mol Psychiatry, 2019.

H. B. Simpson, C. T. Wetterneck, S. P. Cahill, J. E. Steinglass, M. E. Franklin et al., Treatment of Obsessive-Compulsive Disorder Complicated by Comorbid Eating Disorders, Cogn Behav Ther, vol.42, issue.1, pp.64-76, 2013.

F. R. Smink, D. Van-hoeken, and H. W. Hoek, Epidemiology of eating disorders: incidence, prevalence and mortality rates, Curr Psychiatry Rep, vol.14, issue.4, pp.406-414, 2012.

M. Soichot, Variabilité génétique du métabolisme du tryptophane et troubles du comportement sous alcool. Th D Biologie-Santé, 2011.

M. Solinas, Z. Justinova, S. R. Goldberg, and G. Tanda, Anandamide administration alone and after inhibition of fatty acid amide hydrolase (FAAH) increases dopamine levels in the nucleus accumbens shell in rats, J Neurochem, vol.98, issue.2, pp.408-419, 2006.

F. Solmi, M. C. Mascarell, S. Zammit, J. B. Kirkbride, and G. Lewis, Polygenic risk for schizophrenia, disordered eating behaviours and body mass index in adolescents, Br J Psychiatry J Ment Sci, pp.1-6, 2019.

L. Souaiby, C. Gauthier, M. Poirier, J. Olié, R. Gaillard et al., Antidépresseurs : aspects thérapeutiques, EMC -Psychiatrie, vol.14, issue.1, pp.1-14, 2016.

C. Spadone and M. Glikman, Etifoxine, un nouveau regard sur le récepteur GABA et l'anxiété. L'Encéphale, vol.1, pp.1-12, 2008.

L. Steenbergen, R. Sellaro, S. Van-hemert, J. A. Bosch, and L. S. Colzato, A randomized controlled trial to test the effect of multispecies probiotics on cognitive reactivity to sad mood, Brain Behav Immun, vol.48, pp.258-264, 2015.

S. C. Stefano, J. Bacaltchuk, S. L. Blay, and J. C. Appolinário, Antidepressants in short-term treatment of binge eating disorder: Systematic review and meta-analysis, Eat Behav, vol.9, issue.2, pp.129-136, 2008.

H. Steiger, L. Booij, `. E. Kahan, K. Mcgregor, L. Thaler et al., A longitudinal, epigenome-wide study of DNA methylation in anorexia nervosa: results in actively ill, partially weight-restored, long-term remitted and non-eating-disordered women, J Psychiatry Neurosci, vol.44, issue.3, pp.205-213, 2019.

J. E. Steinglass, S. C. Kaplan, Y. Liu, Y. Wang, and B. T. Walsh, The (lack of) effect of alprazolam on eating behavior in anorexia nervosa: A preliminary report: Alprazolam and Eating Behavior in AN, Int J Eat Disord, vol.47, issue.8, pp.901-904, 2014.

J. R. Strawn, L. Geracioti, N. Rajdev, K. Clemenza, and A. Levine, Pharmacotherapy for generalized anxiety disorder in adult and pediatric patients : an evidence-based treatment review, Expert Opin Pharmacother, vol.19, issue.10, pp.1057-1070, 2018.

M. K. Strike, S. Norris, S. Kearney, and M. L. Norris, More than just milk: a review of prolactin's impact on the treatment of anorexia nervosa, Eur Eat Disord Rev, vol.20, issue.1, pp.85-90, 2012.

M. Takaki and N. Okabe, Aripiprazole May Be Effective as an Add-on Treatment in Bulimic Symptoms of Eating Disorders, J Clin Psychopharmacol, vol.35, issue.1, pp.93-95, 2015.

S. Tebeka, G. Airagnes, and F. Limosin, Antipsychotiques : quand et comment les prescrire ? Rev Médecine Interne, vol.38, pp.328-336, 2017.

N. Tennoune, P. Chan, J. Breton, R. Legrand, Y. N. Chabane et al., Bacterial ClpB heat-shock protein, an antigen-mimetic of the anorexigenic peptide ?-MSH, at the origin of eating disorders, Transl Psychiatry, vol.4, issue.10, p.458, 2014.
URL : https://hal.archives-ouvertes.fr/hal-02334069

E. Tibiriça, The multiple functions of the endocannabinoid system : a focus on the regulation of food intake, Diabetol Metab Syndr, vol.2, p.5, 2010.

M. E. Trunko, T. A. Schwartz, L. A. Berner, A. Cusack, T. Nakamura et al., A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control, Borderline Personal Disord Emot Dysregul, vol.4, p.21, 2017.

M. E. Trunko, T. A. Schwartz, V. Duvvuri, and W. H. Kaye, Aripiprazole in anorexia nervosa and lowweight bulimia nervosa: Case reports, Int J Eat Disord, vol.44, issue.3, pp.269-275, 2011.

M. E. Trunko, T. A. Schwartz, E. Marzola, A. S. Klein, and W. H. Kaye, Lamotrigine use in patients with binge eating and purging, significant affect dysregulation, and poor impulse control, Int J Eat Disord, vol.47, issue.3, pp.329-334, 2014.

H. P. Upadhyaya, D. Desaiah, K. J. Schuh, F. P. Bymaster, M. J. Kallman et al., A review of the abuse potential assessment of atomoxetine: a nonstimulant medication for attention-deficit/hyperactivity disorder, Psychopharmacology (Berl), vol.226, issue.2, pp.189-200, 2013.

O. Uzun and B. Ozdemir, Aripiprazole as an augmentation agent in treatment-resistant body dysmorphic disorder, Clin Drug Investig, vol.30, issue.10, pp.707-710, 2010.

M. Valentin, L. Radon, J. Duclos, F. Curt, and N. Godart, Troubles bipolaires et anorexie mentale : une étude clinique. L'Encéphale, vol.45, pp.27-33, 2019.

M. Van-de-wouw, H. Schellekens, T. G. Dinan, and J. F. Cryan, Microbiota-Gut-Brain Axis: Modulator of Host Metabolism and Appetite, J Nutr, vol.147, issue.5, pp.727-745, 2017.

J. Van-liefferinge, A. Massie, J. Portelli, D. Giovanni, G. Smolders et al., Are vesicular neurotransmitter transporters potential treatment targets for temporal lobe epilepsy ?, Front Cell Neurosci, vol.7, p.139, 2013.

. Vidal--norset-15-mg--synthèse,

. Vidal--prozac, , vol.20, 2019.

.. -. Vidal,

. .. Ritaline and .. -. Lp,

E. Indésirables, , 2019.

.. -. Vidal,

.. -. Tdah and . Traitements,

.. -. Vidal,

. -. Trouble and . Traitements,

, VIDAL -Trouble obsessionnel compulsif (TOC) -Prise en charge, 2019.

M. Vosahlikova and P. Svoboda, Lithium -therapeutic tool endowed with multiple beneficiary effects caused by multiple mechanisms, Acta Neurobiol Exp, vol.76, issue.1, pp.1-19, 2016.

B. T. Walsh, C. M. Hadigan, M. J. Devlin, M. Gladis, and S. P. Roose, Long-term outcome of antidepressant treatment for bulimia nervosa, Am J Psychiatry, vol.148, issue.9, pp.1206-1212, 1991.

G. Wang, A. Geliebter, N. D. Volkow, F. W. Telang, J. Logan et al., Enhanced Striatal Dopamine Release During Food Stimulation in Binge Eating Disorder, Obesity, vol.19, issue.8, pp.1601-1608, 2011.

K. Ward and L. Citrome, Lisdexamfetamine : chemistry, pharmacodynamics, pharmacokinetics, and clinical efficacy, safety, and tolerability in the treatment of binge eating disorder, Expert Opin Drug Metab Toxicol, vol.14, issue.2, pp.229-238, 2018.

H. Weingarden, S. S. Mothi, I. Ladis, S. Hoeppner, H. E. Reese et al., D-Cycloserine-Augmented Behavior Therapy for Body Dysmorphic Disorder : A Preliminary Efficacy Trial, Cognit Ther Res, 2019.

C. Westwell-roper and S. E. Stewart, Challenges in the diagnosis and treatment of pediatric obsessive-compulsive disorder, Indian J Psychiatry, vol.61, pp.119-130, 2019.

H. S. White, M. D. Smith, and K. S. Wilcox, Mechanisms of Action of Antiepileptic Drugs, Int Rev Neurobiol, vol.81, pp.85-110, 2007.

M. A. White and C. M. Grilo, Bupropion for overweight women with binge-eating disorder : a randomized, double-blind, placebo-controlled trial, J Clin Psychiatry, vol.74, issue.4, pp.400-406, 2013.

B. D. Woodside and R. Staab, Management of Psychiatric Comorbidity in Anorexia Nervosa and Bulimia Nervosa, CNS Drugs, vol.20, issue.8, pp.655-663, 2006.

J. J. Worthington, G. Kinrys, L. E. Wygant, and M. H. Pollack, Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients, Int Clin Psychopharmacol, vol.20, issue.1, pp.9-11, 2005.

J. M. Yano, K. Yu, G. P. Donaldson, G. G. Shastri, P. Ann et al., Indigenous bacteria from the gut microbiota regulate host serotonin biosynthesis, Cell, vol.161, issue.2, pp.264-276, 2015.

G. S. Yeo and L. K. Heisler, Unraveling the brain regulation of appetite: lessons from genetics, Nat Neurosci, vol.15, issue.10, pp.1343-1349, 2012.

H. Zhang and J. M. Garcia, Anamorelin hydrochloride for the treatment of cancer-anorexia-cachexia in NSCLC, Expert Opin Pharmacother, vol.16, issue.8, pp.1245-1253, 2015.

H. Ziauddeen, S. R. Chamberlain, P. J. Nathan, A. Koch, K. Maltby et al., Effects of the mu-opioid receptor antagonist GSK1521498 on hedonic and consummatory eating behaviour: a proof of mechanism study in binge-eating obese subjects, Mol Psychiatry, vol.18, issue.12, pp.1287-1293, 2013.